Until entirely new treatment regimens such as more efficient immunotherapies, combinatorial inhibition with drugs targeting histone deacetylases (HDACs) or inducing apoptosis (reviewed in [15]) or immunotherapies together with oncolytic viruses [53, 54] as well as personalized cocktails of combined treatments come into practice, more efficient combinations of available and FDA-approved kinase inhibitors could improve progression-free survival of melanoma patients, who are not eligible to BRAF inhibition or have become resistant to this treatment. Here, BRAF is linked to melanoma.